|
Market Closed -
Euronext Paris
11:55:00 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 0.7600 EUR | -6.17% |
|
-11.63% | -20.83% |
| 09-25 | Transgene provides update on its operations |  |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 17.24M | 10.23M | 7.9M | 6.35M | 7.21M | |||||
Total Assets | 102M | 66.44M | 45.22M | 42.17M | 139M | |||||
Interest Expense | -464K | -804K | -168K | -1.68M | -1.31M | |||||
CAPEX | -686K | -1.5M | -2.67M | -3.07M | -842K | |||||
EBT | -19.54M | -32.8M | -22.33M | -33.97M | -37.52M | |||||
D&A | 2.51M | 1.69M | 1.57M | 1.28M | 1.33M | |||||
Operating Income | -23.52M | -29.9M | -30.05M | -35.66M | -35.06M | |||||
Net Income | -19.54M | -32.8M | -22.33M | -33.97M | -37.52M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
France | 17.24M | 10.23M | 7.9M | 6.35M | 7.21M | |||||
Total Assets | 102M | 66.44M | 45.22M | 42.17M | 139M | |||||
Interest Expense | -464K | -804K | -168K | -1.68M | -1.31M | |||||
D&A | 2.51M | 1.69M | 1.57M | 1.28M | 1.33M | |||||
CAPEX | -686K | -1.5M | -2.67M | -3.07M | -842K | |||||
Net Income | -19.54M | -32.8M | -22.33M | -33.97M | -37.52M | |||||
EBT | -19.54M | -32.8M | -22.33M | -33.97M | -37.52M | |||||
Operating Income | -23.52M | -29.9M | -30.05M | -35.66M | -35.06M |
- Stock Market
- Stocks
- TNG Stock
- Financials Transgene
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
